United Therapeutics
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 1996-01-01
- Employees
- -
- Market Cap
- $15.5B
- Website
- http://www.unither.com
Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction
- Conditions
- First Posted Date
- 2007-04-09
- Last Posted Date
- 2007-11-12
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 10
- Registration Number
- NCT00458042
- Locations
- ๐บ๐ธ
UCSD Medical Center Thornton Hospital, La Jolla, California, United States
๐บ๐ธUCSD Medical Center Hillcrest Campus, San Diego, California, United States
Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
- Conditions
- Interventions
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 8
- Registration Number
- NCT00439946
- Locations
- ๐บ๐ธ
THE NEW YORK-PRESBYTERIAN HOSPITAL Weill Cornell Medical Center, New York, New York, United States
๐บ๐ธUniversity of California San Francisco (UCSF) Medical Center, San Francisco, California, United States
๐บ๐ธIntegris Baptist Medical Center, Oklahoma City, Oklahoma, United States
Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin
- First Posted Date
- 2006-09-08
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 10
- Registration Number
- NCT00373360
- Locations
- ๐บ๐ธ
Cleveland Clinic Foundation, Cleveland, Ohio, United States
FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
- Conditions
- Interventions
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 349
- Registration Number
- NCT00325403
- Locations
- ๐บ๐ธ
Harbor-UCLA Medical Center, Torrance, California, United States
๐บ๐ธEmory University Hospital, Atlanta, Georgia, United States
๐บ๐ธUniversity of Chicago Hospitals, Chicago, Illinois, United States
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
- Conditions
- Interventions
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 354
- Registration Number
- NCT00325442
- Locations
- ๐จ๐ฆ
SMBD Jewish General Hospital, Montreal, Quebec, Canada
๐บ๐ธUniversity of Maryland School of Medicine, Baltimore, Maryland, United States
๐บ๐ธUniversity Hospitals of Cleveland, Cleveland, Ohio, United States
Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)
- Conditions
- Interventions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 235
- Registration Number
- NCT00147199
- Locations
- ๐บ๐ธ
UTSW Medical Center, Dallas, Texas, United States
๐บ๐ธTufts Medical Center, Boston, Massachusetts, United States
๐บ๐ธAllegheny General Hospital, Pittsburgh, Pennsylvania, United States
12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.
- Conditions
- First Posted Date
- 2003-09-30
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 72
- Registration Number
- NCT00069511
- Locations
- ๐บ๐ธ
Tulane Univ. Health Sciences Center, New Orleans, Louisiana, United States
๐บ๐ธMemphis Gastroenterology Group, Memphis, Tennessee, United States
๐บ๐ธShands Hospital at the University of Florida, Gainesville, Florida, United States
Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft
- Conditions
- First Posted Date
- 2003-08-13
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT00067041
- Locations
- ๐บ๐ธ
Southern Illinois University School of Medicine, Springfield, Illinois, United States
๐บ๐ธVascular Institute Albany Medical College, Albany, New York, United States
๐บ๐ธOregon Health Sciences University, Portland, Oregon, United States
Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures
- Conditions
- First Posted Date
- 2003-05-20
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT00060996
- Locations
- ๐บ๐ธ
South Carolina Heart Center, Columbia, South Carolina, United States
๐บ๐ธUniversity of Massachusetts Memorial Health, Worcester, Massachusetts, United States
๐บ๐ธMinneapolis Heart Institute, Minneapolis, Minnesota, United States
A Transition Study From Flolanยฎ to Remodulinยฎ in Patients With Pulmonary Arterial Hypertension
- Conditions
- First Posted Date
- 2003-04-16
- Last Posted Date
- 2013-03-07
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT00058929
- Locations
- ๐บ๐ธ
University of Southern California, Los Angeles, California, United States
๐บ๐ธHarbor-UCLA Medical Center, Torrance, California, United States
๐บ๐ธThe Rush Heart Institute Center for Pulmonary Heart Disease, Chicago, Illinois, United States